Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Cardiovascular4053 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00005 | 35258483 | Endocr Connect | Menopause-associated risk of cardiovascular disease. | 2022 | Details |
| A00009 | 35256195 | Thromb Res | Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A00012 | 35255597 | Endocrinol Metab (Seoul) | The Influence of Obesity and Metabolic Health on Vascular Health. | 2022 | Details |
| A00013 | 35255263 | Lancet Oncol | Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. | 2022 | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | 2022 | Details |
| A00070 | 35232007 | Clin Mol Hepatol | NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals. | 2022 | Details |
| A00086 | 35225189 | Br J Nutr | Organ meat consumption and risk of nonalcoholic fatty liver disease: the TCLSIH study. | 2022 | Details |
| A00088 | 35223941 | Front Nutr | Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. | 2022 | Details |
| A00099 | 35220605 | Hepatology | Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles. | 2022 | Details |
| A00107 | 35217817 | Acta Pharmacol Sin | Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. | 2022 | Details |
| A00112 | 35216556 | BMC Endocr Disord | Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. | 2022 | Details |
| A00114 | 35216326 | Int J Mol Sci | New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. | 2022 | Details |
| A00117 | 35215517 | Nutrients | Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases. | 2022 | Details |
| A00126 | 35212997 | Methods Mol Biol | Metabolic Phenotyping in Mice with NASH Using Indirect Calorimetry. | 2022 | Details |
| A00149 | 35208241 | Metabolites | Assessment of Exposure to Di-(2-ethylhexyl) Phthalate (DEHP) Metabolites and Bisphenol A (BPA) and Its Importance for the Prevention of Cardiometabolic Diseases. | 2022 | Details |
| A00153 | 35207239 | J Clin Med | Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. | 2022 | Details |
| A00157 | 35204710 | Biomolecules | Posttranscriptional Regulation of Insulin Resistance: Implications for Metabolic Diseases. | 2022 | Details |
| A00168 | 35203457 | Biomedicines | Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. | 2022 | Details |
| A00173 | 35199429 | HIV Med | "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV". | 2022 | Details |
| A00176 | 35197660 | Acta Inform Med | Biochemical Parameters as Predictors of Underlying Liver Disease in Patients with Chronic Kidney Disorders. | 2021 | Details |
| A00179 | 35196511 | Am J Med Sci | Deciphering the Role of Aquaporins in Metabolic Diseases: A Mini Review. | 2022 | Details |
| A00199 | 35189388 | Clin Gastroenterol Hepatol | Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium. | 2022 | Details |
| A00209 | 35185113 | J Pediatr Gastroenterol Nutr | Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study. | 2022 | Details |
| A00212 | 35183303 | Lancet Diabetes Endocrinol | A global view of the interplay between non-alcoholic fatty liver disease and diabetes. | 2022 | Details |
| A00236 | 35172328 | J Clin Endocrinol Metab | Growth hormone and insulin-like growth factor I regulation of nonalcoholic fatty liver disease. | 2022 | Details |
| A00246 | 35167495 | JCI Insight | Ethnic and gender differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. | 2022 | Details |
| A00249 | 35166009 | Diabetes Obes Metab | Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. | 2022 | Details |
| A00264 | 35162067 | Int J Environ Res Public Health | The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients. | 2022 | Details |
| A00279 | 35154005 | Front Endocrinol (Lausanne) | Novel Subgroups and Chronic Complications of Diabetes in Middle-Aged and Elderly Chinese:A Prospective Cohort Study. | 2022 | Details |
| A00324 | 35134508 | J Nutr Biochem | Mechanisms of autophagic responses to altered nutritional status. | 2022 | Details |
| A00334 | 35131122 | Clin Investig Arterioscler | Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path! | 2022 | Details |
| A00342 | 35127372 | Acta Pharm Sin B | The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy. | 2021 | Details |
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | 2022 | Details |
| A00359 | 35121786 | Sci Rep | Pericardial fat, thoracic peri-aortic adipose tissue, and systemic inflammatory marker in nonalcoholic fatty liver and abdominal obesity phenotype. | 2022 | Details |
| A00364 | 35118444 | touchREV Endocrinol | Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. | 2021 | Details |
| A00385 | 35107763 | Curr Atheroscler Rep | Childhood Hypertriglyceridemia: Is It Time for a New Approach? | 2022 | Details |
| A00390 | 35104757 | Phytomedicine | Seed oil of Rosa roxburghii Tratt against non-alcoholic fatty liver disease in vivo and in vitro through PPARα/PGC-1α-mediated mitochondrial oxidative metabolism. | 2022 | Details |
| A00404 | 35100024 | Circulation | Salt-Induced Hepatic Inflammatory Memory Contributes to Cardiovascular Damage Through Epigenetic Modulation of SIRT3. | 2022 | Details |
| A00405 | 35098442 | Hepatol Int | Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. | 2022 | Details |
| A00438 | 35084136 | Rev Med Suisse | [New approaches to risk and the use of electronic tools in primary care medicine in 2021]. | 2022 | Details |
| A00440 | 35083304 | Front Cardiovasc Med | Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis. | 2022 | Details |
| A00442 | 35082753 | Front Endocrinol (Lausanne) | Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. | 2022 | Details |
| A00445 | 35080136 | J Diabetes Investig | Non-alcoholic fatty liver disease and type 2 diabetes: An update. | 2022 | Details |
| A00446 | 35080048 | J Gastroenterol Hepatol | Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A00451 | 35077243 | J Cardiovasc Pharmacol Ther | The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity. | 2022 | Details |
| A00460 | 35072542 | Antioxid Redox Signal | SPECIALIZED PRO-RESOLVING MEDIATORS DERIVED FROM N-3 POLYUNSATURATED FATTY ACIDS: ROLE IN METABOLIC SYNDROME AND RELATED COMPLICATIONS. | 2022 | Details |
| A00463 | 35071254 | Front Med (Lausanne) | Not Only High Number and Specific Comorbidities but Also Age Are Closely Related to Progression and Poor Prognosis in Patients With COVID-19. | 2022 | Details |
| A00472 | 35068798 | J Clin Exp Hepatol | Diagnosis and Management of Cirrhotic Cardiomyopathy. | 2021 | Details |
| A00477 | 35068225 | Exp Biol Med (Maywood) | Impact of spexin on metabolic diseases and inflammation: An updated minireview. | 2022 | Details |
| A00481 | 35066992 | Liver Int | The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population-based follow-up study (NASHCO). | 2022 | Details |
| A00482 | 35066087 | J Hepatol | Is it time for chronopharmacology in NASH? | 2022 | Details |
| A00485 | 35065166 | Life Sci | Hepatocellular BChE as a therapeutic target to ameliorate hypercholesterolemia through PRMT5 selective degradation to restore LDL receptor transcription. | 2022 | Details |
| A00493 | 35063242 | Clin Nutr ESPEN | Effect of Cornus mas L. fruit extract on lipid accumulation product and cardiovascular indices in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial. | 2021 | Details |
| A00508 | 35058147 | Eur J Intern Med | Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. | 2022 | Details |
| A00519 | 35054478 | Life (Basel) | Deep Sea Water-Dissolved Organic Matter Intake Improves Hyperlipidemia and Inhibits Thrombus Formation and Vascular Inflammation in High-Fat Diet Hamsters. | 2022 | Details |
| A00522 | 35053629 | Children (Basel) | Cardiovascular Risk Factors and Subclinical Atherosclerosis in Greek Adolescents with Polycystic Ovary Syndrome: Its Relationship with Body Mass Index. | 2021 | Details |
| A00545 | 35051649 | Clin Gastroenterol Hepatol | Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. | 2022 | Details |
| A00548 | 35050189 | Metabolites | The Role of Fructose as a Cardiovascular Risk Factor: An Update. | 2022 | Details |
| A00554 | 35048107 | Eur Heart J | Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. | 2022 | Details |
| A00556 | 35047580 | Front Cardiovasc Med | Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes. | 2022 | Details |
| A00578 | 35041626 | Am J Gastroenterol | Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00584 | 35040119 | Eur J Clin Invest | Fatty kidney: A possible future for chronic kidney disease research. | 2022 | Details |
| A00593 | 35036572 | Biol Methods Protoc | Preparation of fatty acid solutions exerts significant impact on experimental outcomes in cell culture models of lipotoxicity. | 2021 | Details |
| A00625 | 35024053 | Cardiovasc Ther | Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes. | 2021 | Details |
| A00628 | 35023183 | Aliment Pharmacol Ther | NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. | 2022 | Details |
| A00631 | 35021995 | BMC Gastroenterol | Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. | 2022 | Details |
| A00634 | 35021057 | Immunity | Inflammation in obesity, diabetes, and related disorders. | 2022 | Details |
| A00637 | 35019905 | Biomater Sci | Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice. | 2022 | Details |
| A00660 | 35011746 | J Clin Med | Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles. | 2021 | Details |
| A00663 | 35010976 | Nutrients | Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. | 2021 | Details |
| A00673 | 35007752 | J Biomed Inform | Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models. | 2022 | Details |
| A00690 | 35002979 | Front Endocrinol (Lausanne) | Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. | 2021 | Details |
| A00694 | 35000203 | Hepatology | Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. | 2022 | Details |
| A00698 | 34998993 | Clin Gastroenterol Hepatol | Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00704 | 34996457 | Lipids Health Dis | NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. | 2022 | Details |
| A00712 | 34992579 | Front Endocrinol (Lausanne) | Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00722 | 34988994 | Aliment Pharmacol Ther | Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. | 2022 | Details |
| A00725 | 34988225 | Biomed Res Int | Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. | 2021 | Details |
| A00737 | 34983637 | Diabetol Metab Syndr | Overweight/obesity in adolescents with type 1 diabetes belonging to an admixed population. A Brazilian multicenter study. | 2022 | Details |
| A00744 | 34981470 | Adv Exp Med Biol | The Effect of Herbal Medicine and Natural Bioactive Compounds on Plasma Adiponectin: A Clinical Review. | 2021 | Details |
| A00747 | 34981313 | Dig Dis Sci | Bariatric Surgery in NAFLD. | 2022 | Details |
| A00752 | 34980174 | J Transl Med | Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. | 2022 | Details |
| A00792 | 34966133 | Curr Opin Lipidol | Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications. | 2022 | Details |
| A00793 | 34965565 | Probl Radiac Med Radiobiol | SUBCLINICAL INFLAMMATION IN NON/ALCOHOLIC FATTY LIVER DISEASE AT THE REMOTE PERIOD AFTER THE CHORNOBYL ACCIDENT. | 2021 | Details |
| A00803 | 34959992 | Nutrients | Curcumin in Metabolic Health and Disease. | 2021 | Details |
| A00805 | 34959901 | Nutrients | Role and Treatment of Insulin Resistance in Patients with Chronic Kidney Disease: A Review. | 2021 | Details |
| A00811 | 34959119 | Biomed Pharmacother | GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease. | 2021 | Details |
| A00812 | 34959080 | J Neurol Sci | Association of chronic liver disease with cognition and brain volumes in two randomized controlled trial populations. | 2021 | Details |
| A00822 | 34957088 | Front Cell Dev Biol | Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer. | 2021 | Details |
| A00845 | 34950560 | Cureus | Study of Endothelial Dysfunction in Patients With Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A00848 | 34950104 | Front Endocrinol (Lausanne) | Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. | 2021 | Details |
| A00885 | 34941988 | J Gastrointestin Liver Dis | The Role of Psychotherapy in the Treatment of Patients with Non- alcoholic Fatty Liver Disease and Obstructive Sleep Apnea. | 2021 | Details |
| A00890 | 34939092 | Eur J Prev Cardiol | Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. | 2022 | Details |
| A00903 | 34933963 | Open Heart | Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. | 2021 | Details |
| A00915 | 34931492 | Hepatol Commun | Alcohol Consumption and Cardiovascular Outcomes in Patients With Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. | 2021 | Details |
| A00920 | 34929391 | Clin Gastroenterol Hepatol | Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016. | 2021 | Details |
| A00925 | 34927450 | J Am Heart Assoc | Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. | 2021 | Details |
| A00927 | 34927277 | Aliment Pharmacol Ther | Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. | 2021 | Details |
| A00944 | 34922811 | J Diabetes Complications | DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. | 2021 | Details |
| A00945 | 34922644 | Lancet Diabetes Endocrinol | Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. | 2021 | Details |